First AIFA Institutional Mission to Japan

AIFA President Robert Nisticò led the first-ever institutional mission to Japan, accompanied by Board Advisor Emanuele Monti and Dr. Armando Magrelli from the International Relations Office. The delegation held bilateral meetings with the Japanese Ministry of Health and PMDA (Pharmaceuticals and Medical Devices Agency) under President Yasuhiro Fujiwara, discussing shared regulatory challenges including research and innovation, longevity and chronic disease management, polypharmacy in elderly patients, AI in regulatory affairs, and healthcare system sustainability. Both nations, sharing universal healthcare systems, identified this mission as a foundation for future cooperation and best-practice exchange between Italian and Japanese pharmaceutical regulators.

AIFA Approves AIFA Ascolta and AIFA Incontra Stakeholder Engagement Regulations

AIFA has definitively approved and published in the Gazzetta Ufficiale the regulations for two new stakeholder engagement initiatives: AIFA Ascolta, a structured dialogue space for patient associations, networks, and federations focused on improving pharmaceutical access and health protection; and AIFA Incontra, a privileged dialogue channel between the Agency and institutional, scientific, industrial, and civic stakeholders in the pharmaceutical and health sectors. Both initiatives include a Transparency Register that will make meeting objectives, participants, final reports, and related documentation publicly available on the Agency's website. Meetings under both programs will typically be scheduled on a quarterly basis.

Precision Medicine: Tailored Therapies Replace One-Size-Fits-All Care

AIFA published a dossier on April 17, 2026, examining the clinical and economic impact of precision medicine and pharmacogenomics in Italy's National Health Service. The document highlights that 68% of Italians over 65 receive at least five different drug prescriptions and 28.5% take ten or more medications, increasing risks of drug interactions and adverse reactions. AIFA President Robert Nisticò emphasized that precision medicine should be a right for all patients, not a luxury, and positioned pharmacogenomics as a bridge between genetic knowledge and daily clinical practice.

Serie Generale 93: Legislative Decrees, Municipal Dissolutions, Drug Authorizations

The Official Gazette Serie Generale No. 93 of 22 April 2026 publishes 14 distinct official acts spanning legislative decrees, presidential decrees, ministerial orders, and regulatory communications. Key items include Legislative Decree No. 51 of 2 April 2026 transposing EU Regulation 2023/2411 on geographical indications for craft and industrial products, three presidential decrees dissolving municipal councils in Simeri Crichi, Sarnico, and Maracalagonis with appointment of extraordinary commissioners, and five AIFA communications modifying or granting marketing authorizations for human medicines (Berates, Allopurinolo EG Stada, Sacubitril e Valsartan Pensa, Ampenaia, Brivaracetam Amarox). Reconstruction ordinances from the Extraordinary Commissioner for 2016 earthquake cover public and private reconstruction timelines, church reconstruction plans, and public works reconstruction for Marche and Umbria regions following 2022-2023 seismic events.

Contratti Pubblici n.45: Ultra-Broadband Grants, 2 Auctions

The Italy Official Gazette (Serie Speciale - Contratti Pubblici n. 45 del 22-4-2026) publishes a procurement notice from INVITALIA S.p.A. for public grants to finance ultra-broadband network investment projects (codice redazionale TX26BFM192), alongside two real estate auction notices from Comune di Caselle Torinese (TX26BIA194) and Comunità Montana Valli del Verbano (TX26BIA193) for the sale of properties including the 'Pradaccio' complex. These notices provide opportunities for telecommunications companies and infrastructure investors to participate in Italian public procurement.

Guidance on Investigator Brochure Content for ATMP Clinical Trials

The Danish Medicines Agency has published guidance on the required content of the Investigator's Brochure for clinical trials involving Advanced Therapy Medicinal Products (ATMPs). The guidance integrates the ICH GCP IB format description with ATMP-specific recommendations from the EMA guideline on ATMPs in clinical trials. Sponsors and clinical investigators conducting ATMP trials should review the guidance and ensure their Investigator's Brochures align with these requirements.

PRAC Concludes NAION Is Very Rare Side Effect of Ozempic, Rybelsus, Wegovy

PRAC completed its safety assessment concluding that NAION (non-arteritic anterior ischemic optic neuropathy) is a very rare side effect of semaglutide medicines. Product information for Ozempic, Rybelsus, and Wegovy was updated on 30 September 2025 to include this finding. The frequency classification of 'very rare' means the side effect may affect fewer than 1 in 10,000 people. As of May 2025, the Danish Medicines Agency had received 28 reports of NAION in patients treated with semaglutide; by October 2025, this had risen to 32 Danish reports (14 Ozempic, 17 Wegovy, 1 both Ozempic and Rybelsus).

Taste of India 1 Denied 19 Oregon Workers Overtime, DOL Recovers $200K

The U.S. Department of Labor's Wage and Hour Division investigation found Taste of India 1 in McMinnville, Oregon violated the Fair Labor Standards Act by misclassifying 19 workers as exempt, failing to pay overtime premiums, and using an invalid tip pool arrangement. The division recovered $200,137 in back wages and $15,256 in civil money penalties assessed for willful violations. Employers in the food service industry should review their exempt status classifications and tip pool arrangements for compliance.

FY 2025-26 Q2 MQA Quarterly Performance Report Released

The Florida Department of Health's Division of Medical Quality Assurance (MQA) has released the FY 2025-26 Quarterly Performance Report for Quarter Two, covering MQA's key trends in licensing, enforcement, and information along with insights into MQA's financials. The report is required under sections 456.005 and 456.025(9), Florida Statutes, and provides quarterly snapshots of key performance statistics for MQA staff, decision-makers, board and council members, consumers, and other stakeholders. The announcement also references MQA initiatives including HB 975 Cleared to Care campaign, MQA's Virtual Agent ELI, and unlicensed activity outreach activities.

Imdylltra Positive CHMP Opinion for Extensive-Stage Small Cell Lung Cancer

The European Medicines Agency's CHMP, with Dutch participation through CBG-MEB, issued a positive opinion recommending Imdylltra (tarlatamab) for marketing authorization as an immunotherapy for adults with extensive-stage small cell lung cancer (ES-SCLC). The opinion is based on a study of over 500 patients showing longer survival compared to standard treatment. The most serious side effects include cytokine-release syndrome and neurological inflammation. The opinion has been forwarded to the European Commission for final decision on marketing authorization.

CBG-MEB Issues Registration Call for Lithium Carbonate Tablets to Address Medicine Shortages

CBG-MEB is publishing a call for registration of lithium carbonate 200mg, 300mg, and 400mg tablets as part of its new initiative to address urgent medicine shortages where prolonged unavailability is expected. Lithium carbonate is used to stabilise mood swings in patients with bipolar disorder, treating and preventing manic and depressive episodes. Marketing authorisation holders or companies interested in bringing these medicines to the Dutch market can contact CBG-MEB directly to explore registration pathways.

Netherlands Temporarily Authorizes Vaxxon Clone ND Vaccine Amid EU Shortage

The Bureau Diergeneesmiddelen (BD) has granted temporary authorization for Vaxxon Clone, an ND vaccine not approved on the EU market, for use in the Netherlands. The authorization addresses an acute shortage caused by reduced production of SPF eggs (needed for live vaccine production) due to bird flu cullings at suppliers, combined with increased demand from ND outbreaks in Poland since October 2025 and now in Germany. Commercial poultry keepers and turkey farmers in the Netherlands, where ND vaccination is mandatory, should verify their vaccination status and source supply through the temporary authorization mechanism.

AEMPS 2026 Work Plan Details Five Strategic Objectives for the Year

AEMPS published its 2026 Annual Work Plan on March 27, 2026, outlining objectives aligned with its 2023–2026 Strategic Plan. The five strategic objectives cover guaranteeing supply of human medicines, combating antimicrobial resistance, strengthening Spain's positioning in European and Ibero-American pharmaceutical networks, optimising processes including AI-based solutions, and improving human resources and information technology capabilities. The plan draws from AEMPS's ordinary operations, specific action plans, and the European BEMA V benchmarking programme.

EU Opens 60-Day Public Consultation on PFAS Restriction Affecting Pharmaceuticals

The Socio-Economic Analysis Committee (SEAC) of ECHA has opened a 60-day public consultation on its provisional opinion on restricting perfluoroalkyl and polyfluoroalkyl substances (PFAS), published on 20 April 2026. The RAC's opinion is already final and concludes restriction is justified to protect human health and the environment, citing PFAS persistence, dispersion, bioaccumulation, and potential toxic effects including reproductive harm and cancer risk. The SEAC opinion, expected to be finalised by end of 2026, may include specific exemptions for uses where no alternatives exist. The European Commission will then develop a regulatory proposal under REACH for Member State voting.

MiPLUS Help: Apply, Renew, Track License Online

The Michigan Professional Licensing User System (MiPLUS) is the Department of Licensing and Regulatory Affairs, Bureau of Professional Licensing's online licensing and regulatory database application for health and occupational professionals in Michigan. The system enables applicants to apply online, track application status, and receive electronic notifications, while licensees can renew licenses and modify existing licensing information. This help page provides instructions for registration, application, modification, and renewal processes using MiPLUS.

Michigan Board of Nursing Meeting Agendas and Minutes 2025–2026

The Michigan Board of Nursing maintains a public index of board meeting agendas and disciplinary subcommittee meeting minutes, organized by date in reverse chronological order. Documents span from January 2025 through April 2026 and include both full board and disciplinary subcommittee materials, with several agendas marked as amended. PDFs are hosted by the Michigan Department of Licensing and Regulatory Affairs (LARA) Bureau of Professional Licensing.

Michigan Board of Nursing Authority Origins and Membership

The Michigan Board of Nursing publishes its authority origins and current membership composition. The Board was originally created under the Nurse Practice Act of 1909, with authority transferred to the Nursing Practice Act of 1967 and finally to the Public Health Code of 1978. The Public Health Code establishes the Board's powers including nurse licensure qualifications, education program standards, competency assurance, and disciplinary authority. The Board consists of 24 members: 9 registered nurses, 1 nurse midwife, 1 nurse anesthetist, 1 nurse practitioner, 3 licensed practical nurses, and 8 public members. The page lists current named members with their represented seats and term expiration dates through June 2029.

Family Violence Witnesses Gain Alternative Evidence-Giving Options in NZ Family Court

The Evidence (Giving Family Violence Evidence in Family Court Proceedings) Amendment Act 2025 establishes new legislative protections allowing witnesses in family violence proceedings to give evidence via courtroom screens, closed circuit TV from witness rooms, or audio visual link from external locations—removing the requirement to testify from an open witness box. The entitlement applies to proceedings commenced on or after 26 February 2026, with witnesses required to notify the court and opposing party at least 28 days before the hearing.

Parliament Amends Alcohol Sales Law, Effective 3rd April

The Sale and Supply of Alcohol (Sales on Anzac Day morning, Good Friday, Easter Sunday and Christmas Day) Amendment Act 2026 comes into force on 3 April 2026, amending the law regarding the sale of alcohol by on-licences, cellar doors and RSAs on restricted trading days. The Ministry of Justice advises licensees to seek independent legal advice as a Local Alcohol Plan or other specific licence conditions may affect what they can or cannot do on a restricted trading day.

Gorodetskiy v. Honeywell International Inc. — Advancement Denied

Delaware Court of Chancery denied plaintiff Mikhail Gorodetskiy's motions for default judgment and summary judgment while granting defendant Honeywell International Inc.'s motion to dismiss in this advancement-of-expenses dispute. The court held that Gorodetskiy failed to satisfy the contractual prerequisites under Article Eleventh of Honeywell's Certificate of Incorporation, including the undertaking requirement, when he initially sent his February 2025 demand letter without an executed undertaking. The court further denied plaintiff's claim for fees-on-fees. The underlying insolvency action against Gorodetskiy arises from his former role as CEO of LLC UOP, a Russian subsidiary Honeywell wound down following the 2022 invasion of Ukraine.

Belgian Penal Code Implementation Delayed to September 2026

The Belgian government announced on March 20, 2026, that the entry into force of the new Penal Code is postponed from April 8 to September 1, 2026. The Cabinet's decision, made in the restricted committee, must still be confirmed by Parliament. Federal and regional departments are expected to ensure their regulations are aligned with the new Penal Code during the transitional period.

SPF Justice Strategic Plan 2026-2029 Signed by Minister Verlinden

SPF Justice signed its 2026-2029 strategic plan on 10 February 2026 with Minister Annelies Verlinden and Acting President Mathilde Steenbergen. The plan formalises shared commitments with the federal government and serves as a reference framework for implementing political and administrative priorities. Key priorities include a more accessible justice system, strengthening trust, service quality, a human-centred approach, and the central role of staff in achieving these goals. Annual operational plans will translate strategy into concrete projects and actions.

Belgium Kosovo Sign Criminal Judicial Cooperation Agreement

Belgium and Kosovo signed a new bilateral judicial cooperation agreement on April 22, 2026, updating mutual legal assistance provisions for criminal cases. The agreement covers witness and suspect hearings via videoconference, extended asset seizure and confiscation regimes, joint investigation teams, and data protection guarantees. It replaces the obsolete 1971 agreement between Belgium and the former Yugoslavia, with ratification procedures now underway.

NY Nursing Board Advisory Notices Index

The NY Nursing Board hub page lists nine advisory notices including a workforce survey requirement for registered professional nurses, New York's BSN in 10 law, mandated reporter training updates, and COVID-19 resources. The page serves as a central index for NY-licensed nurses and employers to access multiple regulatory updates from a single location. No single compliance obligation or deadline is established by this index page itself.

2025 Science Award Winners, CAR T-Cell Therapy Research Listed

The Paul-Ehrlich-Institut published its 2025 press release archive listing award winners including the Langen Junior Science Award 2025 and Langen Science Award 2025. Research achievements highlighted include CAR T-cell therapy, targeted gene therapy, SARS-CoV-2 studies, and β-glucan adjuvants for allergy treatment. The listing also includes the 10th anniversary of #MedSafetyWeek.

PEI 2024 Press Release Archive

This archive page lists 13 press releases published by the Paul-Ehrlich-Institut (PEI) throughout 2024, ranging from 16 February to 20 December 2024. Topics covered include the appointment of Professor Stefan Vieths as President, research findings on COVID-19 treatments and vaccines, hepatitis studies, CAR T-cell immunotherapy safety research, allergy research, and participation in the EU imSAVAR consortium for immunotherapy safety. No compliance obligations or regulatory changes are created by this index page.

Revolutionary War Quarter Released at Mount Vernon

The US Mint and George Washington's Mount Vernon celebrated the release of the Revolutionary War Quarter on March 23, 2026. The quarter, the second coin in the 2026 Semiquincentennial Circulating Coin Program, was released to Federal Reserve Banks for distribution to financial institutions. The coin features a Continental Army soldier at Valley Forge on the reverse and was authorized by the Circulating Collectible Coin Redesign Act of 2020 (Public Law 116-330).

2026 American Innovation $1 Coin Rolls and Bags Featuring Wisconsin on Sale April 7

The United States Mint announces that 2026 American Innovation $1 Coin Rolls and Bags featuring Wisconsin will be available for purchase starting Tuesday, April 7 at noon EDT. The reverse design depicts the Cray-1 supercomputer, the first commercially successful supercomputer built from 1976 to 1982 and known as the world's fastest computer at the time. Product options include 100-coin bags priced at $154.50 and 25-coin rolls priced at $61.00, with orders limited to 10 per household per product type.

Emerging Liberty Dime Sets $40, Bags $54, Available April 17

The United States Mint announces the availability of 2026 Semiquincentennial Emerging Liberty Dime Two-Roll Sets and Bags beginning April 17 at noon EDT. Two product options are offered: a bag containing 200 circulating-quality dimes minted in Philadelphia and Denver priced at $54.00 (product code 26SDB), and a two-roll set containing 100 circulating-quality dimes priced at $40.00 (product code 26SDR).

Swissmedic Therapeutic Products Safety Communications DHPCs Batch Recalls

Swissmedic publishes consolidated listings of Direct Healthcare Professional Communications (DHPCs), Health Professional Communications (HPCs), batch recalls, and quality defect notices for human medicinal products, medical devices, and veterinary medicines. The listings include dates, affected product names, and the nature of the safety issue (e.g., potential visible particles after reconstitution, risk of severe hypercalcaemia, non-conforming sterility testing). No specific compliance actions or deadlines are imposed by this aggregation page itself.

How Patients Report Suspected Drug Side Effects in Switzerland

Swissmedic publishes guidance on adverse drug reaction reporting in Switzerland, informing patients, relatives, and healthcare professionals of their reporting pathways. Healthcare professionals must report serious or unknown adverse reactions within 15 days of diagnosis and non-serious reactions within 60 days, while pharmaceutical companies have their own reporting gateway via the ElViS portal. Patients and relatives can now report suspected side effects electronically through Swissmedic's dedicated web form without requiring medical expertise.

FAQ About mRNA COVID-19 Vaccine Safety

Swissmedic published a comprehensive FAQ addressing common questions about mRNA COVID-19 vaccine safety, efficacy against variants, common side effects, and authorization status. The FAQ confirms that vaccines continue to protect against severe COVID-19 disease and that temporary authorizations are under review for ordinary authorization. Healthcare professionals and consumers can access the latest information on potential adverse reactions and vaccination recommendations.

Judge Makes 4,000 Woo Requests to Municipalities

A judge from the North Holland District Court made over 4,000 Woo (Public Access to Government Information Act) requests to municipalities nationwide to investigate how they handle confidentiality obligations under the Woo law. The court was not informed in advance, and the matter emerged after a tip from the legal profession in mid-September 2025. The judge has been suspended from hearing cases pending review by the Procureur-Generaal bij de Hoge Raad, which is examining whether the conduct creates an appearance of bias given that the same municipalities could appear as parties in cases before the court.

Henk Naves: Judicial Council Must Practice Self-Criticism

Henk Naves, chair of the Raad voor de Rechtspraak (Dutch Judicial Council), has published commentary in the 2025 annual report calling on the judiciary to practice self-criticism and engage in critical self-reflection. Naves emphasizes that the judicial system functions because society grants judges independence and lifetime appointments, which requires corresponding accountability. The Council processed approximately 1.5 million decisions in 2025 and highlighted systemic bottlenecks including nitrogen-dossier impacts on affected parties and persistent shortages in youth care chains.

Netherlands Judiciary Annual Report 2025: 1.5M Decisions

The Dutch Rechtspraak published its 2025 annual report, recording nearly 1.5 million judicial decisions made in 2025, with a roughly equal number of new cases filed at courts. The judiciary employs more than 13,500 people, comprising 10,821 Rechtspraak staff and 2,715 judges and senior judges, of whom 258 were in training. Online published rulings on rechtspraak.nl increased from 63,700 in 2024 to 71,300 in 2025. This annual statistical report provides insight into the judiciary's performance, staffing levels, and composition for compliance monitoring and public accountability purposes.

New Online Application Tracker for MA Nursing Licensure Is Live

The Massachusetts Board of Registration in Nursing launched a newly designed online application tracker on April 8, 2026, available to new applicants seeking nursing licensure and advanced practice authorization. The tracker provides real-time visibility into application review stages, estimated processing times, and status updates, along with contact resources for applicant inquiries. This is an administrative process improvement; no new compliance obligations, fees, or regulatory requirements are imposed on applicants.

Japan PMDA Drug Safety Alerts, 16 Alerts Listed

PMDA publishes a reference index of 16 drug safety alerts for healthcare professionals, covering drug classes including COVID-19 treatments (Xocova, Lagevrio), DPP-4 inhibitors, benzodiazepine receptor agonists, and drugs such as lamotrigine, thiamazole, and benzbromarone. Alerts range from Alert No. 1 (August 2010) through Alert No. 16 (December 2024), with several marked as revised. The English version is noted as a convenience translation with the Japanese original prevailing in case of inconsistency.

Dear Healthcare Professional Letters - Emergent and Rapid Drug Safety Communications

PMDA maintains an index of Dear Healthcare Professional Letters (DHPCs) communicating drug safety information to medical institutions in Japan. The letters are categorized as Yellow Letters (emergent and important safety information requiring immediate communication) and Blue Letters (prompt but non-emergent safety information). The index lists nine DHPCs issued between August 2011 and June 2021, covering drugs including Verzenio (abemaciclib), Lamictal (lamotrigine), Xeplion (paliperidone), and others, each with associated case reports. Marketing authorization holders are required under Article 68-10 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices to take necessary measures including recall, suspension of sales, and information provision when drugs may cause public health hazards.

Ongoing Drug Safety Evaluations, Risk Information

PMDA and MHLW publish ongoing drug safety evaluations for drugs marketed in Japan, including HPV vaccines (bivalent and quadrivalent) and Bevacizumab (genetical recombination). The page summarises two evaluation categories: risk information supported by accumulated ADR reports or EPPV data, and risk information flagged by foreign regulatory agencies or published studies where PMDA and MHLW have commenced review. Completed evaluations are moved to the Revisions of PRECAUTIONS webpage, and patients are advised not to discontinue treatment without consulting a physician.

New AVA Rulings: TTB Proposes Champlain Valley of Vermont and Establishes Nashoba Valley and Nine Lakes AVAs

TTB has published both a proposed rule and final rules related to American Viticultural Areas (AVAs). TTB proposes to establish the 'Champlain Valley of Vermont' AVA (comments due May 26, 2026), and has established two new AVAs: the 'Nashoba Valley' AVA in Worcester County, Massachusetts, and the 'Nine Lakes of East Tennessee' AVA in northeastern Tennessee. Both final rules are effective April 23, 2026. None of these new AVAs are located within or contain any existing AVA.

Japan and Timor-Leste Sign Justice Cooperation Memorandum

On 5 March 2026, Minister of Justice HIRAGUCHI Hiroshi of Japan and Minister of Justice Sergio de Jesus Fernandes da Costa Hornai of Timor-Leste signed a Memorandum of Cooperation between their respective ministries. The signing ceremony took place in Tokyo and was followed by a meeting where both ministers discussed promoting cooperation in the field of law and justice between the two nations.

German Delegation Meets State Minister MITANI, 6th Apr

On 6 April 2026, State Minister MITANI Hidehiro of Japan received a courtesy visit from a delegation of the Committee on Legal Affairs and Consumer Protection of the German Federal Parliament. The delegation head, Mr. Carsten Müller, and State Minister Mitani exchanged views on the use of AI in the legal field. Both parties reaffirmed that the Ministry of Justice of Japan and the German Federal Parliament will maintain and further develop their cooperative relationship in the field of law and justice.

Japan Vietnam Justice Ministers Meet, 16th Mar

On 16 March 2026, Mr. HIRAGUCHI Hiroshi, Minister of Justice of Japan, received a courtesy visit by H.E. Mr. Phan Chi Hieu, Deputy Minister of Justice of the Socialist Republic of Viet Nam. The two ministers reaffirmed that the Ministry of Justice of the two countries would maintain and further develop their cooperative relationship through the newly launched Japan-Vietnam LEAD (Legal Exchange And Development) joint research project.

EU Announces €235 Million Humanitarian Aid for West and Central Africa

The European Commission has announced €235 million in humanitarian assistance to support the most vulnerable populations in West and Central Africa. Funding is distributed across eight countries and one regional programme: Central Sahel (€75M), Cameroon (€16.6M), Central African Republic (€22M), Chad (€72M), Mauritania (€4.8M), Nigeria (€33M), coastal countries (€6M), and regional projects (€6.4M). Commissioner Hadja Lahbib highlighted that the region faces a convergence of conflict, hunger, instability, and climate shocks, with over 12.4 million people in the Central Sahel alone requiring humanitarian assistance.

Commissioner Kos Opens Third EU-Ukraine Business Summit in Brussels

Commissioner for Enlargement Marta Kos and Ukraine's Deputy Prime Minister Taras Kachka opened the third EU-Ukraine Business Summit in Brussels on 22 April 2026, bringing together over 1,000 business leaders, policymakers, and investors over two days. The summit aims to mobilise private and public investment for Ukraine's recovery ahead of the Ukraine Recovery Conference in Poland, with the EU's Ukraine Investment Framework providing €9.5 billion in guarantees and grants expected to mobilise up to €40 billion in investments by 2027. The Commission continues to welcome investment proposals through its Calls for Expressions of Interest, particularly from EU-Ukrainian joint ventures in key industrial sectors.

EU Commission Recommendation on Removing Barriers to Power Purchase Agreements

The European Commission has published a Recommendation on removing barriers to the development of Power Purchase Agreements (PPAs) and other energy purchase agreements. PPAs are long-term bilateral contracts between generators and corporate consumers that facilitate construction of new clean energy installations and provide price certainty. The recommendation follows a 4-week call for evidence and addresses bottlenecks including access for small buyers, guarantees, accounting rules, and guarantees of origin.

Japan-Led ISO Motorway ADS Standards Published: ISO 23792-1 and ISO 23792-2

Japan, serving as convenor of ISO/TC204/WG14, has led the development of two new international standards for Motorway Chauffeur Systems: ISO 23792-1:2026 (published March 27, 2026) covering framework and general requirements, and ISO 23792-2:2026 (published March 19, 2026) covering discretionary lane change requirements and test procedures. The standards establish baseline functionality requirements and test procedures for Level 3 Automated Driving Systems on motorways to support global ADS market expansion while reducing traffic accidents caused by human error.

Japan Establishes Task Force to Secure Medical Supplies Due to Middle East Situation

METI and the Ministry of Health, Labour and Welfare have established a joint Task Force to secure supplies of medical products including pharmaceuticals, medical devices, and medical supplies that may be affected by the situation in the Middle East. The Task Force held its first meeting at 11:30 a.m. on March 31, 2026, and will operate behind closed doors to encourage frank discussion. The Task Force aims to implement comprehensive approaches including analysis of challenges in ensuring stable supplies and discussion of possible responses to the situation.

Special Economic Measures (Russia) Regulations – Comprehensive Prohibitions

The Special Economic Measures (Russia) Regulations, enacted under SEMA, impose comprehensive sanctions including asset freezes on designated persons, export and import restrictions, and financial prohibitions. The regulations prohibit Canadians and persons in Canada from dealing in property of designated persons, providing financial services, exporting goods to Russia for offshore oil/shale/arctic exploration, importing Russian petroleum products and coal, and shipping luxury goods. Additional prohibitions cover arms exports, jet fuel, chemicals, diamonds, maritime transport services for Russian crude oil, and aviation insurance and reinsurance services. Three regulatory amendments were registered in 2025-2026, most recently on March 25, 2026.

Trump Account $1,000 Contribution Eligibility for Children Born 2025-2028

The USVI Bureau of Internal Revenue informs individual taxpayers about a new Trump Account benefit available to children born after 2024 and before 2029 who are U.S. citizens. Parents, guardians, and authorized individuals may elect to establish a Trump Account and receive a $1,000 federal contribution for eligible children by filing IRS Form 4547 electronically at TrumpAccounts.gov or by mail to the IRS in Austin, TX. The Treasury Department will send account-opening information starting in May 2026.